Treatment results of modified BFM protocol in pediatric high-risk Burkitt lymphoma

Vural S., Genc D. B., Kebudi R., Dogan O., Karaman S.

TURKISH JOURNAL OF PEDIATRICS, vol.63, no.4, pp.639-647, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 63 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.24953/turkjped.2021.04.011
  • Journal Name: TURKISH JOURNAL OF PEDIATRICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.639-647
  • Keywords: Burkitt lymphoma, BFM, methotrexate, NON-HODGKIN-LYMPHOMA, HIGH-DOSE METHOTREXATE, B-CELL MALIGNANCIES, CHILDREN, CHEMOTHERAPY, ADOLESCENTS, EXPERIENCE, CHILDHOOD, THERAPY, INVOLVEMENT
  • Istanbul University Affiliated: Yes

Abstract

Background. Chemotherapy with high dose methotrexate is the mainstay of treatment for Burkitt lymphoma (BL), especially to manage central nervous system (CNS) disease. However, methotrexate administration requires close drug level monitoring for appropriate folinic acid rescue, which might not be readily available in all centers. In this study, we assessed the long-term treatment outcomes of a modified Non-Hodgkin lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM) 90 regimen in pediatric high-risk BL without CNS involvement.